Table 1 Comparative analysis of demographic, clinical and laboratory data among study groups
Variable | DM (n = 425) | New onset DM (n = 384) | IGT (n = 560) | IFG (n = 376) | NGT (n = 782) |
|---|---|---|---|---|---|
Age (yrs) | 65.5 ± 9.5* | 65.3 ± 10.4* | 62.3 ± 10.3* | 58.2 ± 11.0 | 57.0 ± 11.3 |
Male – no. (%) | 241 (56.7)* | 237 (61.6)* | 395 (70.5)* | 316 (82.4) | 618 (79.0) |
Smoking – no. (%) | 166 (39.1)* | 182 (47.4)* | 319 (56.9)* | 245 (65.1) | 533 (68.2) |
Hypertension – no. (%) | 320 (75.3)* | 218 (56.9)* | 302 (53.9)* | 167 (44.3) | 325 (41.6) |
Hyperlipidaemia – no. (%) | 232 (54.5) | 200 (52.1) | 295 (52.6) | 208 (55.2) | 411 (52.5) |
Peripheral vascular disease – no. (%) | 42 (9.9) | 41 (10.8) | 48 (8.5) | 23 (6.1) | 61 (7.8) |
Creatinine on admission (μmol\L) | 104.3 ± 86.6* | 92.1 ± 39.2* | 85.9 ± 34.0 | 80.3 ± 18.7* | 85.5 ± 42.5 |
GFR (mL/min/1.73 m2) | 73.3 ± 26.7* | 77.6 ± 25.6* | 84.5 ± 25.2* | 92.5 ± 24.5* | 89.2 ± 25.6 |
Contrast-induced nephropathy – no. (%) | 110 (25.8)* | 127 (33.2)* | 150 (26.8)* | 79 (21.1) | 133 (17.0) |
Previous myocardial infarction – no. (%) | 113 (26.5)* | 75 (19.6) | 95 (16.9) | 61 (16.3) | 132 (16.9) |
Previous CABG – no. (%) | 16 (3.8) | 10 (2.7) | 12 (2.2) | 10 (2.7) | 26 (3.3) |
Previous PCI – no. (%) | 63 (14.8)* | 31 (8.2) | 54 (9.6) | 26 (7.0) | 66 (8.4) |
Glucose on admission (mmol/L) | 12.2 ± 5.4* | 9.6 ± 4.1* | 7.8 ± 2.5* | 7.2 ± 2.0 | 7.2 ± 2.2 |
Pain duration (hours) | 7.9 ± 9.9* | 7.9 ± 10.5* | 5.8 ± 6.6 | 5.7 ± 5.9 | 5.9 ± 7.4 |
Killip-class on admission | 1.3 ± 0.7* | 1.4 ± 0.8* | 1.3 ± 0.6* | 1.2 ± 0.5 | 1.2 ± 0.5 |
Anterior infarction – no. (%) | 144 (33.8) | 150 (39.1)* | 195 (34.8) | 143 (37.9)* | 242 (31.0) |
Ejection fraction (%) | 42.0 ± 8.4* | 42.8 ± 8.3* | 43.8 ± 7.8* | 44.9 ± 7.7 | 45.7 ± 7.0 |
Fibrinolysis – no. (%) | 10 (2.3) | 10 (2.5) | 21 (3.8) | 8 (2.1) | 31 (4.0) |
GP IIb/IIIa – inhibitor – no. (%) | 68 (16.0)* | 66 (17.3)* | 80 (14.3) | 58 (15.5)* | 84 (10.8) |
Beta-adrenergic blocker – no. (%) | 372 (87.6) | 338 (88.1) | 498 (88.9) | 327 (87.0) | 702 (89.8) |
ACE-inhibitor/ARB – no. (%) | 369 (86.9) | 328 (85.4) | 483 (86.2) | 320 (85.2) | 672 (85.9) |
Aspirin – no. (%) | 414 (97.4) | 376 (98.0) | 549 (98.0) | 369 (98.2) | 769 (98.3) |
Statin – no. (%) | 357 (83.9) | 323 (84.0) | 471 (84.1) | 312 (83.1) | 658 (84.2) |
Clopidogrel/Ticlopidine – no. (%) | 369 (86.9) | 335 (87.2) | 488 (87.1) | 325 (86.4) | 683 (87.4) |
Multivessel coronary artery disease –no (%) | 322 (75.8)* | 252 (65.7)* | 346 (61.7) | 222 (59.1) | 456 (58.3) |
Incomplete revascularization – no. (%) | 240 (56.5)* | 177 (46.1) | 264 (47.1) | 172 (45.8) | 328 (41.9) |
TIMI flow <3 after PCI of IRA – no. (%) | 63 (14.9)* | 70 (18.1)* | 72 (12.8) | 45 (12.1) | 77 (9.8) |
Hospitalization time (days) | 9.8 ± 7.9* | 10.3 ± 6.2* | 8.9 ± 4.6* | 7.7 ± 2.6 | 7.6 ± 4.3 |